Shares in BioMarin Pharmaceutical (BMRN) are under pressure as investors react to a scientific update that focuses on early-stage and investigational data rather than near-term commercial catalysts. The imaging results for Voxzogo in children with achondroplasia were described as encouraging. But the emphasis on long-acting BMN 333 and on hypochondroplasia points to a development-heavy story that may not quickly translate into stronger earnings.

Patients with blindness caused by retinitis pigmentosa regained the ability to detect objects in a small trial of a treatment based on research that won the 2026 Nobel Prize in Physiology or Medicine, demonstrating the potential of a novel approach.

Steris (STE) will buy privately held Xodus Medical for $2.1bn, adding surgical products designed to improve safety for patients and operating-room staff to its healthcare consumables business.

Bristol Myers Squibb (BMY) said a lower dose of its experimental drug slowed the progression of a serious lung-scarring disease, putting it on track to become a first-of-its-kind treatment if approved.

Alnylam Pharmaceuticals (ALNY) faces securities fraud scrutiny linked to a sharp reduction in sales expectations for its TTR franchise, raising fresh questions about how reliably the portfolio can underpin future profits. The legal uncertainty arrives as the stock still trades at a premium price-to-earnings multiple to many biotech peers, a valuation built on its RNAi platform and ATTR portfolio.

Viatris (VTRS) has agreed to buy Pacira BioSciences (PCRX) for $1.65bn in cash. The deal adds two non-opioid pain treatments to its portfolio as the drugmaker tries to build out higher-value branded medicines beyond its core generics business.

Bayer (BAYN) is to invest $2.2bn in a new manufacturing site in New Albany, Ohio, as its pharmaceuticals division seeks to increase its revenue in the US.

BioMarin Pharmaceutical (BMRN) is cutting 117 jobs at its Novato, California, site, just months after trimming staff in New Jersey following an acquisition.

BridgeBio (BBIO), the maker of Attruby, is relaunching its "Don't Pass on Your Heart Health" campaign with a new approach, as it seeks to close the awareness gap around transthyretin amyloid cardiomyopathy (ATTR-CM).

An advisory panel to the US Food and Drug Administration has handed Grail (GRAL) a milestone win for its Galleri blood test, concluding that the early cancer detection test's potential benefits outweigh its risks and moving it a step closer to approval.

Florida's attorney-general has sued Pfizer (PFE) and its chief executive Albert Bourla, accusing the drugmaker of misleading consumers about the safety and effectiveness of its Covid-19 vaccine.

CSL (CSL.AX) has agreed to co-develop and co-promote an experimental treatment for rare kidney and liver diseases with Swiss drugmaker Alentis Therapeutics, in a deal worth up to $1.6bn, excluding development funding.

Sanofi (SAN) and Regeneron (REGN) have agreed to develop four new drugs together in a deal worth up to $8bn and to settle prior litigation, a move analysts said signals a reset of their strained partnership and an early victory for Sanofi's new chief executive, Belen Garijo.

AbbVie (ABBV) said it would take part in a US government pilot designed to test a new rebate system for discounted medicines, joining a group of large drugmakers that includes Amgen (AMGN), AstraZeneca (AZN), and Bristol Myers Squibb (BMY).

The four largest pharmacy benefit managers controlled 75 per cent of the US market in 2024, up from 70 per cent two years earlier, according to a report from the American Medical Association.

Novartis (NOVN) has agreed a licensing deal worth up to $7.8bn with China's Abogen to develop therapies based on messenger RNA, underscoring the Swiss drugmaker's growing interest in an emerging class of treatments.

InnoCare Pharma (688428.SS) has signed a research collaboration and licensing agreement with Eli Lilly (LLY) worth up to about $3.35bn, the Chinese drugmaker announced.

Roche (RHHBY) has agreed a deal with Atavistik Bio worth almost $2bn, including milestone payments, to develop oral treatments for cardiovascular, kidney and metabolic diseases.

Mirum Pharmaceuticals (MIRM) said that its experimental treatment for hepatitis delta reduced levels of the virus in patients, meeting the primary goal of a late-stage study.

Merck (MRK) said that its injectable treatment for diabetic macular edema, a serious eye disease affecting people with diabetes, was as effective as the current standard of care at improving visual sharpness in a late-stage clinical trial.